Company Description
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas.
Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
The company’s lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials.
It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer’s Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors.
The company was founded in 2017 and is headquartered in Bethesda, Maryland.
| Country | United States |
| Founded | 2017 |
| IPO Date | Mar 18, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Gene Mack M.B.A. |
Contact Details
Address: 4800 Hampden Lane, Suite 200 Bethesda, Maryland 20814 United States | |
| Phone | (301) 500-1556 |
| Website | gaintherapeutics.com |
Stock Details
| Ticker Symbol | GANX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001819411 |
| CUSIP Number | 36269B105 |
| ISIN Number | US36269B1052 |
| Employer ID | 85-1726310 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthias Alder LIC. IUR., LL.M. | President, Chief Executive Officer and Director |
| Dr. Khalid Islam Ph.D. | Founder and Chairman |
| Gene Mack M.B.A. | Chief Financial Officer |
| Dr. Manolo Bellotto Ph.D. | GM and Chief Strategy Officer |
| Dr. Joanne Taylor Ph.D. | Senior Vice President of Research |
| Dr. Terenzio Ignoni Pharm.D. | Senior Vice President of Technical Operations |
| Dr. Jonas Hannestad M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 12, 2024 | 8-K | Current Report |
| Jul 9, 2024 | 8-K | Current Report |
| Jul 1, 2024 | FWP | Free Writing Prospectus |
| Jun 28, 2024 | 8-K | Current Report |
| Jun 25, 2024 | 8-K | Current Report |
| Jun 17, 2024 | 424B5 | Filing |
| Jun 14, 2024 | 8-K | Current Report |
| Jun 13, 2024 | 424B5 | Filing |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |